X

Trial Profile

Pilot Study to Investigate the Safety and Efficacy of Avelumab Monotherapy in Patients With Advanced or Metastatic Adenocarcinoma of the Small Intestine

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 18 Apr 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avelumab (Primary)
Indications Adenocarcinoma; Intestinal cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

22 Mar 2022 Status changed from active, no longer recruiting to discontinued due to low accrual.
25 Jan 2020 Results assessing safety and efficacy of avelumab in small bowel adenocarcinoma presented at the 2020 Gastrointestinal Cancers Symposium
19 Aug 2019 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com